12/02/2019

Company News

<p>Emmes today announced that it is part of a team of medical centers, universities and private industry supporting the development of a “universal influenza vaccine” that could provide longer-lasting protection than current vaccines and combat a wider variety of influenza viruses.</p>
<p>This is part of the newly launched Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, under the direction of the National Institute of Allergy and Infectious Diseases (NIAID). According to NIAID, which is part of the National Institutes of Health, the network of research centers will work together in a coordinated, multidisciplinary effort to develop more durable, broadly protective and longer-lasting influenza vaccines.</p>
<p>Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “This project builds upon our experience in supporting clinical trials of influenza vaccines and other emerging infectious diseases, such as Zika and Ebola. It’s exciting to be on the ground floor of this innovative program for NIAID.”</p>
<p>Emmes is working with two other companies to provide the data management and statistical support for the CIVICs program. Digital Infuzion is the prime contractor, with Emmes and Gryphon Scientific, LLC, as subcontractors. All three companies are headquartered in Maryland. </p>
<p>According to the Centers for Disease Control and Prevention, influenza causes hundreds of thousands of hospitalizations and tens of thousands of deaths every year. The time it can take to develop vaccines, plus the fact that existing vaccines do not always protect against the continually changing strains of influenza, led to the new NIAID program.</p>
<p>The Digital Infuzion, Gryphon Scientific and Emmes team members are responsible for<br />
designing statistically sound preclinical experiments and clinical trials. Other focuses include performing data analyses, making results available across the CIVICs program, and ensuring that data is available in publicly accessible databases.</p>
<p>Dr. Stephan Bour, chief scientific officer for Digital Infuzion, said, “Emmes is a great addition to our team. The company has more than 30 years of experience with NIAID and has built an outstanding reputation in statistical and data management. We look forward to building our partnership and making a strong contribution to this important strategic endeavor.”</p>
<p>Dr. Lindblad added, “Emmes has been expanding our presence in the Maryland biotech community, and it’s a pleasure to collaborate with Digital Infuzion. The company is known for using technology and bioinformatics to develop novel solutions for the health care industry.”</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;
<p>This project has been funded in whole or in part with Federal funds from the National Institute of Allergy & Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00078.</p>

11/25/2019

Company News

<p>Emmes today announced that Lynn Lewis has joined the company as chief business officer, a newly created position. Her overall focus is to build deeper relationships with existing clients and to develop new business opportunities, particularly among biotech and pharmaceutical companies.</p>
<p>Lewis will be responsible for sales, marketing, communications, strategic planning and partnerships, and proposal development.</p>
<p>Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “Lynn understands the importance of science in our business. She will extend our reputation and value as a trusted scientific partner with those who share our passion for designing and executing important studies aimed at improving human health.” </p>
<p>She added, “Lynn’s experience and accomplishments in sales and marketing complement the capabilities of our executive management team. She has a history of driving the development of new products and services for pharmaceutical companies globally.”</p>
<p>Lewis began her career at Eli Lilly & Company, a leading global pharmaceutical firm based in Indianapolis, Indiana. She held numerous positions in sales, marketing, strategic planning and general management. Her final role there was as project team leader, and she led a global scientific and commercial team to gain U.S. and European approvals for Forteo, an osteoporosis product. She then spent 15 years at Covance Inc., a contract research organization based in Princeton, New Jersey, serving biopharmaceutical companies. There, she started as vice president of global sales, marketing and commercial development for one of its divisions. She was subsequently promoted to positions with increasing sales and marketing responsibilities, including group vice president for business development, clinical development and commercialization services. Before joining Emmes, Lewis was chief commercial officer for Envigo, a contract research organization based in Somerset, New Jersey, serving biopharmaceutical and other life sciences companies. During her 18-month tenure, her team achieved the highest sales level in company history.</p>
<p>“I’m looking forward to building a strong business development team here at Emmes,” said Lewis. “My goal is to develop people and processes that extend the company’s reputation as a government research partner and generate new private sector relationships.”</p>
<p>Lewis has a Master of Business Administration in international business and marketing from the University of North Carolina’s Kenan-Flagler Business School and a Bachelor of Science in biology from Bucknell University. She lives in McCordsville, Indiana.</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;

10/10/2019

Company News

<p>Emmes today announced the award of eight new task order contract awards associated with the Helping to End Addiction Long-termSM Initiative, known as the NIH HEAL InitiativeSM. The total value for the eight contracts is more than $9 million. The contract awards’ duration ranges from one to five years.</p>
<p>The National Institutes of Health launched the HEAL Initiative in April 2018 to improve prevention and treatment strategies for opioid misuse and addiction and enhance pain management. The eight Emmes contract awards are among 375 grants, contracts, and cooperative agreements across 41 states made by the National Institutes of Health in fiscal year 2019 to apply scientific solutions to reverse the national opioid crisis. </p>
<p>“The new contracts recognize our 10-year track record for providing data and statistics support to the research sponsored by NIH’s National Institute for Drug Abuse (NIDA),” said Dr. Paul Van Veldhuisen, Emmes’ chief operating officer. “It’s extremely satisfying for our company and our staff to join with leading researchers across the country in combatting the opioid epidemic.”</p>
<p>As the data and statistical center for the NIDA-sponsored National Drug Abuse Treatment Clinical Trials Network, or CTN, Emmes will play a critical role supporting the enhancement of the CTN to address opioid research. This enhancement will include activities to improve access to high-quality addiction treatment, including studies of the delivery of Opioid Use Disorder (ODU) in general medical settings, as well as ways to prevent the progression of moderate to severe ODU.</p>
<p>Emmes will be responsible for establishing systems for data collection and management; designing and performing statistical analyses; reviewing and monitoring the quality of data and clinical trial progress; preparing study reports; and supporting manuscripts for publication.</p>
<p>Dr. Anne Lindblad, Emmes’ president and chief executive officer, noted, “This new work truly reflects our mission to bring statistical solutions and dedicated research to the most pressing human health problems of our time.”</p>
<p>The company plans to hire about 10 additional staff members with statistical, data management and IT skills to work on the new contracts.</p>
<p>According to the NIH, the initiative is leveraging expertise from almost every NIH institute and center to approach the crisis from all angles and disciplines, and across the full spectrum of research.</p>
<p>"It's clear that a multi-pronged scientific approach is needed to reduce the risks of opioids, accelerate development of effective non-opioid therapies for pain and provide more flexible and effective options for treating addiction to opioids," said NIH Director Francis S. Collins, M.D., Ph.D., who launched the initiative in early 2018. "This unprecedented investment in the NIH HEAL Initiative demonstrates the commitment to reversing this devastating crisis."</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;

09/30/2019

Company News

<p>Emmes today announced that it was ranked as one of the 100 largest private companies in the Washington metropolitan area. The ranking is compiled annually by the Washington Business Journal.</p>
<p>The company was ranked as the 83rd largest private company this year. Its most recently reported revenues were more than $114 million, and about 600 of the company’s 725 employees work in the Washington area.</p>
<p>Earlier this year, Emmes received a Workplace Excellence Seal of Approval award from Alliance for Workplace Excellence. The award recognized organizations committed to<br />
building excellent places to work, considering attributes like innovative corporate culture and management practices, family-friendly policies and programs, employee growth and learning opportunities, and a commitment to corporate responsibility. </p>
<p>Emmes also had been honored with a Gold Award from the Maryland Department of Health, which salutes businesses in the state that are committed to improving employee health and well-being. </p>
<p>“We are continuing to grow and invest in our people,” noted Dr. Anne Lindblad, president and chief executive officer of Emmes. “It’s an honor to be recognized as a leading private company and to receive recognition for our culture and values.</p>
<p>“We will continue to be creative and proactive in building an environment that enhances the development and opportunities for our team,” she added. “That way, they can focus on what they love to do: to collaborate with leading researchers in developing clinical trials and producing research that addresses the health needs of people representing all ages and walks of life.”</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;

07/24/2019

Company News

<p>Emmes today announced that it has received a Workplace Excellence Seal of Approval from Alliance for Workplace Excellence (AWE). This is the fifth consecutive year the company has received the AWE Workplace Excellence award.</p>
<p>The <a href="https://www.excellentworkplace.org/&quot; target="_blank">AWE</a> created the annual recognition program to honor organizations that show an exemplary commitment to building excellent places to work in Montgomery County, Maryland, and throughout the United States. Workplace Excellence winners are evaluated on such attributes as innovative corporate culture and management practices, family-friendly policies and programs, employee growth and learning opportunities, and a commitment to corporate responsibility.</p>
<p>Emmes also received a Health & Wellness Seal of Approval from the AWE for innovative programs promoting employee health and wellness. The AWE award considered employee health fairs, support for physical activity and healthy eating programs, health risk assessments, educational programs on healthy lifestyle, and incentives for participation in wellness programs. </p>
<p>In addition to the AWE recognition, Emmes was honored with a Gold Award from the Maryland Department of Health. Its Healthiest Maryland Businesses Wellness at Work Awards program salutes businesses in the state that are committed to improving employee health and well-being. </p>
<p>According to the Maryland Department of Health, Healthiest Maryland Businesses is a collaborative of Maryland businesses with a shared mission of improving health through worksite wellness efforts.</p>
<p>There are three awards – gold, silver and bronze – and Emmes’ Gold Award acknowledged the well-established workplace wellness practices that promote a culture of health at all levels and utilize policy, programming, benefits, and environmental supports to improve employee health.</p>
<p>Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “We are so proud to be honored with both the Workplace Excellence Seal of Approval and the two Health & Wellness awards. Our leadership team continues to listen to what employees want, and we have created and improved programs and activities that enrich our employees’ lives and make us an even better place to build a career.”</p>
<p>Lindblad added, “Our company was founded on a dedication to research that addresses the health needs of people representing all ages and walks of life. The fact that we have been selected for awards relating to health and wellness makes it even more gratifying.”</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;

04/02/2019

Company News

<p>Emmes today announced that it provided the data management support for a <a href="https://www.nih.gov/news-events/news-releases/acyclovir-labeling-now-in…;, funded by the National Institutes of Health (NIH) and approved by the Food and Drug Administration (FDA), to safely use Acyclovir to treat infants infected with the Herpes Simplex Virus. Acyclovir, known by the brand name Zovirax, now includes recommended usage and dosage for newborns and infants up to three months of age on its label.</p>
<p>The Best Pharmaceuticals for Children Act (BPCA) mandates that NIH prioritize therapeutic areas in critical need for pediatric labeling, sponsor pediatric clinical trials, and submit the data to the FDA for consideration for labeling changes. The clinical trials are sponsored by the National Institute of Child Health and Human Development (NICHD), with the labeling reviews and approvals administered by the FDA.</p>
<p>In the NIH news release, Dr. Perdita Taylor-Zapata, BPCA program lead at NICHD, stated: “With this label change, healthcare providers have clear guidance on how to use and prescribe this drug for their youngest patients.”</p>
<p>Newborns can become infected with the virus during pregnancy, labor and delivery, or shortly after birth if the mother develops genital herpes near the end of her pregnancy. The Herpes Simplex Virus in newborns can cause death or long-term problems such as blindness and damage to the brain and other organs.</p>
<p>Emmes has served as a data coordinating center for the BPCA <a href="https://secure.emmes.com/emmesweb/news?page=1">contract</a&gt; since August 2009. This entails study design, data management, regulatory support, pharmacovigilance, site monitoring, and statistical analyses. </p>
<p>Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “This is one of our largest contracts and one that our Emmes team is extremely proud to support. Our role as a data coordinating center is a critical step in the process to study drugs and therapies used for infants and children and determine whether drug labeling updates are needed.”</p>
<p>The Best Pharmaceuticals for Children Act was enacted in 2002 and subsequently reauthorized by the U.S. Congress in 2007, 2012 and 2017. One of its goals involves conducting clinical trials and research for on- and off-patent drug products meriting further study for children. NICHD activities are aimed at improving pediatric drug therapies through preclinical and clinical testing that lead to drug labeling change.</p>
<p>Most new drugs that have potential applications in pediatric care must be tested in children prior to receiving marketing approval in the U.S. However, the majority of previously approved drug therapies have not been labeled specifically for children and are used off-label without adequate studies in children.</p>
<p>Acyclovir is the first BPCA drug labeling change in 2019, and others are likely to follow. </p>
<p>Lindblad added, “Nine other drugs associated with this BPCA project are in various stages of review at the FDA. Ultimately, what this means is that more infants, young children and teenagers will benefit from careful labeling and appropriate treatment options for a variety of diseases.”</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;

10/30/2018

Company News

<p>The Emmes Corporation today announced that it was named one of the largest women-owned businesses in the Washington metropolitan area by the Washington Business Journal. Emmes was ranked the sixth largest women-owned business in the Washington region, up from number seven last year.</p>
<p>Last month, Emmes was named as one of the top 100 largest private companies in the area. Emmes ranked 83rd, up from 95th the previous year, in the Washington Business Journal’s annual list.</p>
<p>The company’s revenues increased 17 percent, from $90 million in 2016 to $106 million in 2017. This is the third consecutive year Emmes was included in both the top private company and top women-owned business lists. </p>
<p>“Growing the company is a credit to our staff, whose scientific and public health credentials and client relationships have helped us gain recognition as a sizable and successful international clinical research firm,” said Dr. Anne Lindblad, president and chief executive officer of Emmes. “Employees have a wide range of opportunities to design clinical trials for new drugs and to conduct research on the best treatment options for diseases.”</p>
<p>She added, “Even though we enjoy the benefits of a large company, we’ve worked hard to maintain a small-company spirit. We have built programs to make sure that employees have a voice in how the company is run, and we’ve created opportunities to interact, volunteer in the community, and have fun. We have an informal atmosphere where open doors are the norm; bureaucracy and layers are kept to a minimum.”</p>
<p>Emmes opened two new offices in the Washington area over the last 1-1/2 years, in part to accommodate growth and in part to give employees a choice of where to work. </p>
<p>“We wanted to reduce commuting times and be more family-friendly,” noted Dr. Lindblad. “People can choose to work in either Rockville or Frederick, Maryland, or in Northern Virginia. We’re also a proponent of teleworking, and a growing number of employees work from home.”</p>
<p>Earlier this year, Emmes was one of only two biotech companies recognized by The Washington Post in its <a href="https://www.washingtonpost.com/graphics/2018/business/top-workplaces/?n…; target="_blank">Top Workplaces</a> ranking. This was the company’s third consecutive year on the list, which showcases area organizations with the highest ratings from their employees. Emmes also received a <a>Workplace Seal of Approval</a> for the fourth time.</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;

05/09/2018

Company News

<p><em>Most comprehensive Department of Defense-sponsored clinical trial on hyperbaric oxygen for mild traumatic brain injury yields promising findings for future research</em></p>
<p>The Emmes Corporation today announced that scientists and health professionals from the company, LDS Hospital in Salt Lake City, Utah, Lovelace Biomedical Environmental Research Institute in Albuquerque, New Mexico, and the U.S. Army Medical and Materiel Development Activity at Fort Detrick, Maryland, have completed a multi-year clinical trial testing hyperbaric oxygen as an intervention for U.S. military service members who have suffered mild traumatic brain injuries with persistent symptoms.</p>
<p>The Department of Defense-sponsored study included both active duty and veterans in the military who suffered from mild traumatic brain injuries. </p>
<p>Eleven researchers, as well as members of the study team, collaborated to write a paper that summarized the findings. The paper was just published in the Undersea and Hyperbaric Medicine Journal.</p>
<p>Millions of people in the United States deal with traumatic brain injuries, and combat military personnel have increased risk for persistent post-concussive symptoms. This clinical research studied military personnel with post-concussive symptoms three months to five years after mild traumatic brain injury. The randomized clinical trial evaluated participants’ specific symptoms, as well as a range of other assessments such as quality of life, sleep, cognitive processing, auditory, visual and neuroimaging. </p>
<p>Hyperbaric oxygen produced short-term improvement in self-reported post-concussive and post-traumatic stress disorder (PTSD) symptoms, as well as some cognitive processing speed and sleep measures, in comparison to a control group. These improvements regressed after six months, however. One notable finding was that improvements were most significant in trial participants suffering from both traumatic brain injury and PTSD.</p>
<p> “Results suggest that hyperbaric oxygen may have a favorable effect that merits further study in service members, especially in those with PTSD,” said Dr. Lin Weaver, principal investigator and a member of the Hyperbaric Medicine Department of LDS Hospital. “This could be a promising avenue for further research.”</p>
<p>Dr. Steffanie Wilson, Emmes biostatistician and principal investigator of Emmes’ data analysis and management center for the research team, said, “We are planning to produce more in-depth papers on the findings of this study.” She added that additional research could address such issues as dosing, length of treatment and patient selection. </p>
<p>According to Dr. Anne Lindblad, president and chief executive officer of Emmes, “We learned a great deal from this research, from design to outcomes to logistics. This will be extremely helpful in developing more efficient clinical trials in the future and ultimately more effective ways to treat brain injuries and PTSD.”</p>
<p>About the Paper<br />
The paper was published in the March/April issue of the Undersea and Hyperbaric Medicine Journal. Non-subscribers can access the paper for a nominal fee. </p>
<p>About the Contract<br />
This material is based upon work supported by the Department of Defense under Contract No. W81XWH-15-D-0039-0003. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. In the conduct of research where humans are the subjects, the investigator(s) adhered to the policies regarding the protection of human subjects as prescribed by Code of Federal Regulations (CFR) Title 45, Volume 1, Part 46; Title 32, Chapter 1, Part 219; and Title 21, Chapter 1, Part 50 (Protection of Human Subjects).</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;

04/23/2018

Company News

<p>The Emmes Corporation today announced the creation of an internship program in which the company will offer one fellow from Egypt’s Children Cancer Hospital an internship to gain training and experience in clinical research. Under the new program, one fellow will be selected each year to travel to Emmes’ headquarters in Rockville, Maryland, to work with its clinical research experts. The duration of each internship will be determined on a case-by-case basis. </p>
<p>Dr. Anne Lindblad, president and chief executive officer of Emmes, explained that the internship program was a natural extension of the company’s recent education efforts in Egypt. Emmes’ Dr. Ashraf El Fiky and Dr. Robert Lindblad were keynote speakers at the 53rd Alexandria Congress on Allergy and Immunology in Alexandria, Egypt. The conference, scheduled from February 21 to 23, was attended by leading allergy and immunology specialists from Egyptian universities.</p>
<p>Following that conference, El Fiky, Emmes’ clinical trials medical officer for drug safety and pharmacovigilance, and Lindblad, vice president and chief medical officer, traveled to Cairo to speak at an event at the Children Cancer Hospital. They spoke about cancer clinical trials at the First Symposium on Clinical Research in Oncology and Good Clinical Practice Guidelines on February 25.</p>
<p>The Children Cancer Hospital is the largest pediatric oncology hospital in the Middle East. According to El Fiky, “Our new internship program recognizes the hospital’s important role in providing free pediatric oncology services to patients in the region. Its joint fellowship programs with Harvard Medical School, the Dana-Farber Cancer Institute and St. Jude Children’s Research Hospital are great role models. Emmes is truly proud to support the clinical research community in Egypt.”</p>
<p>Two years ago, Emmes had hosted members of the senior management team from Cairo’s Children Cancer Hospital as part of a tour that included the National Institutes of Health and other area biohealth organizations. </p>
<p>“We’re excited to continue to collaborate with Egypt’s medical community and academic institutions and expand our new relationships,” said Dr. Anne Lindblad. “We believe our internship program demonstrates this commitment, and we look forward to hosting our first fellow later this year.”</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;

03/28/2018

Company News

<p>The Emmes Corporation today announced the completion of a pivotal clinical trial for a new product developed by IDx that could help in detecting diabetic retinopathy, the leading cause of blindness in the United States. IDx-DR is a fully autonomous AI-based diagnostic system that analyzes images of the retina for signs of diabetic retinopathy, providing instructions for follow-up care based on the level of disease detected. IDx-DR has been granted expedited review by the Food and Drug Administration.</p>
<p>Under contract to IDx, Emmes was responsible for overall clinical operations, site selection and data management. The clinical trial, which was conducted at 10 sites across the U.S., evaluated 900 patients for the accuracy of IDx-DR to detect moderate to severe diabetic retinopathy, as well as macular edema. IDx, an Iowa City-based company, was founded by world renowned retina specialists and is a leader in automated medical image analysis. </p>
<p>“IDx and Emmes make a stellar team,” said Dr. Anne Lindblad, president and chief executive officer of Emmes. “Our decades of ophthalmology-related research, combined with IDx’ innovative products and AI expertise, paved the way for a pivotal clinical trial with great potential.”</p>
<p>According to Dr. Michael Abramoff, founder and president of IDx, “When you have ground-breaking technology that will change the way medicine is practiced, it’s always a challenge to develop a study that will adequately assess whether it is safe for patient care. Emmes has been a great partner along the way in helping us accomplish this.”</p>
<p>Abramoff is optimistic about the trial results, which demonstrated that the IDx-DR system exceeded performance goals. If cleared by the FDA, IDx-DR is expected to become the first autonomous, AI-based diagnostic system to be used in the front lines of health care.</p>
<p>Dr. Nilay Shah, medical officer and project director for Emmes, said this was the first AI-related study for the company. “We believe artificial intelligence offers great promise for the early detection of many diseases, and we hope our work with IDx will pave the way for more AI-based research and treatment opportunities.”</p>
<p>The FDA is expected to make a determination on the IDx-DR system in the coming months.</p>
<p>About Emmes<br />
We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at <a href="http://www.emmes.com">www.emmes.com</a>.</p&gt;